This antibody binds to SLAMF7 on myeloma cells, simultaneously activating NK cells and macrophages through the SLAMF7-EAT2 interaction and stimulating the FYN/Syk-PI3K-Akt/mTOR signaling pathway. The gene discussed is SH2D1B; the disease is plasma cell myeloma.